3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
137
Carcinoma, Non-Small-Cell Lung
38
Carcinoma, Renal Cell
33
Neoplasm Metastasis
32
Prostatic Neoplasms
22
Brain Neoplasms
21
Lung Neoplasms
20
Pancreatic Neoplasms
19
Uveal Melanoma
17
Neoplasms
17
Carcinoma, Hepatocellular
13
Breast Neoplasms
13
Sarcoma
12
Skin Neoplasms
10
Kidney Neoplasms
10
Urinary Bladder Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
9
Glioblastoma
9
Triple Negative Breast Neoplasms
8
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Carcinoma, Transitional Cell
8
Small Cell Lung Carcinoma
7
Multiple Myeloma
7
Colonic Neoplasms
7
Clear-cell metastatic renal cell carcinoma
7
Recurrence
6
Myelodysplastic Syndromes
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Uterine Cervical Neoplasms
5
Interventions
Gemcitabine
11
Albumin-Bound Paclitaxel
7
Taxes
5
130-nm albumin-bound paclitaxel
4
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Fluorouracil
3
dehydroftorafur
2
Oxaliplatin
2
Losartan
2
Leucovorin
2
Irinotecan
2
Cisplatin
2
niraparib
1
irinotecan sucrosofate
1
folfirinox
1
durvalumab
1
X-Rays
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
S 1 (combination)
1
Resistance Training
1
Radiotherapy, Image-Guided
1
Radiosurgery
1
Radiation
1
Panitumumab
1
Pancreaticoduodenectomy
1
Optical Imaging
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pancreatic Adenocarcinoma
×
Ipilimumab
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts